logo
Plus   Neg
Share
Email

QSC Q3 Revenues Rise Sequentially; Sees Revenue Growth In Q4 - Quick Facts

German Cloud and ICT provider QSC AG (QSCGF) reported Tuesday that its third-quarter revenues were 32.3 million euros, following the sale of its telecommunications subsidiary Plusnet.

Sequentially, revenues grew 7 percent from 30.1 million euros recorded in the second quarter, excluding Plusnet.

The Cloud business, with its two areas of Cloud Services and Internet of Things or IoT, posted third-quarter revenues of 10.2 million euros, 24 percent higher than in the previous quarter.

Consulting revenues grew 4 percent to 10.5 million euros. At 7.0 million euros, Outsourcing revenues were in line with expectations, as were the Colocation revenues of 4.6 million euros.

Looking ahead, CEO Jürgen Hermann said, "QSC is now a growth company once again. And we have budgeted revenue growth for the current fourth quarter as well."

This will be aided by ongoing high volumes of new orders.

QSC will publish its third quarter results on November 11.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>